AR038765A1 - Formulacion en solucion inhalable con una sal de tiotropio - Google Patents

Formulacion en solucion inhalable con una sal de tiotropio

Info

Publication number
AR038765A1
AR038765A1 ARP010105088A ARP010105088A AR038765A1 AR 038765 A1 AR038765 A1 AR 038765A1 AR P010105088 A ARP010105088 A AR P010105088A AR P010105088 A ARP010105088 A AR P010105088A AR 038765 A1 AR038765 A1 AR 038765A1
Authority
AR
Argentina
Prior art keywords
phenyl
water
preparation according
tiotropium
drug preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased/Invalidation/Refusal/Rejection/Nullification
Application number
ARP010105088A
Other languages
English (en)
Spanish (es)
Inventor
Drechsel Karin Dr
Niklaus-Humke Barbara Dr
Schmelzer Christel Dr
Petra Barth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7661727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR038765(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR038765A1 publication Critical patent/AR038765A1/es
Ceased/Invalidation/Refusal/Rejection/Nullification legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
ARP010105088A 2000-10-31 2001-10-31 Formulacion en solucion inhalable con una sal de tiotropio Ceased/Invalidation/Refusal/Rejection/Nullification AR038765A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10054042 2000-10-31

Publications (1)

Publication Number Publication Date
AR038765A1 true AR038765A1 (es) 2005-01-26

Family

ID=7661727

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105088A Ceased/Invalidation/Refusal/Rejection/Nullification AR038765A1 (es) 2000-10-31 2001-10-31 Formulacion en solucion inhalable con una sal de tiotropio

Country Status (33)

Country Link
EP (1) EP1335729A2 (de)
JP (1) JP4559703B2 (de)
KR (1) KR100983208B1 (de)
CN (1) CN1237970C (de)
AR (1) AR038765A1 (de)
AU (2) AU2174102A (de)
BG (1) BG66425B1 (de)
BR (1) BR0115016A (de)
CA (1) CA2427583C (de)
CZ (1) CZ305033B6 (de)
DE (1) DE10152369A1 (de)
EA (1) EA009068B1 (de)
EC (1) ECSP034570A (de)
EE (1) EE05343B1 (de)
HK (1) HK1060569A1 (de)
HR (1) HRP20030337A2 (de)
HU (1) HUP0301377A3 (de)
IL (2) IL155676A0 (de)
ME (1) ME00242B (de)
MX (1) MXPA03003750A (de)
MY (1) MY132777A (de)
NO (1) NO332524B1 (de)
NZ (1) NZ526024A (de)
PE (1) PE20020518A1 (de)
PL (1) PL361001A1 (de)
SA (1) SA01220503B1 (de)
SK (1) SK288031B6 (de)
TW (1) TWI296934B (de)
UA (1) UA76435C2 (de)
UY (1) UY26991A1 (de)
WO (1) WO2002036591A2 (de)
YU (1) YU33103A (de)
ZA (1) ZA200303045B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60114865T2 (de) 2000-04-28 2006-07-27 Kosan Biosciences, Inc., Hayward Heterologe herstellung von polyketiden
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2004279438A1 (en) * 2003-10-09 2005-04-21 Inverseon, Inc. Methods for treating diseases and conditions with inverse agonists
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
CA2595791C (en) * 2005-03-16 2013-10-08 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
US20070274925A1 (en) * 2006-05-26 2007-11-29 Dey, L.P. Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
CN100446770C (zh) * 2007-01-10 2008-12-31 上海现代药物制剂工程研究中心有限公司 丙酸培氯米松水雾剂
TR200907237A2 (tr) * 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Tiotropyum kuru toz kombinasyonu
CN116173025A (zh) * 2018-07-26 2023-05-30 四川海思科制药有限公司 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
CN111971034A (zh) * 2018-07-26 2020-11-20 四川海思科制药有限公司 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4203306A1 (de) * 1992-02-06 1993-08-12 Ig Spruehtechnik Gmbh Asthma oder pulmonal-aerosolzubereitungen mit lecithin
DK0835098T3 (da) * 1995-06-27 2002-10-07 Boehringer Ingelheim Pharma Stabilt lægemiddelpræparat til frembringlese af drivgasfrie aerosoler
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
BR9709650A (pt) * 1996-06-04 1999-08-10 Procter & Gamble Aerosol nasal contendo um esteróide intransal e um anti-histamínico
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
JPH10298107A (ja) * 1997-04-25 1998-11-10 Taisho Pharmaceut Co Ltd 医薬組成物
DK1102579T3 (da) * 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen

Also Published As

Publication number Publication date
CZ20031487A3 (cs) 2003-09-17
YU33103A (sh) 2006-05-25
MEP40708A (en) 2011-02-10
AU2174102A (en) 2002-05-15
BR0115016A (pt) 2005-05-03
SK5262003A3 (en) 2003-10-07
AU2002221741B2 (en) 2007-04-05
EE200300202A (et) 2003-10-15
CN1473044A (zh) 2004-02-04
KR100983208B1 (ko) 2010-09-20
CA2427583C (en) 2008-02-12
HUP0301377A2 (hu) 2003-10-28
DE10152369A1 (de) 2002-05-08
NO332524B1 (no) 2012-10-08
PL361001A1 (en) 2004-09-20
CA2427583A1 (en) 2002-05-10
ME00242B (de) 2011-05-10
MXPA03003750A (es) 2004-10-15
EP1335729A2 (de) 2003-08-20
SK288031B6 (sk) 2012-12-03
EA009068B1 (ru) 2007-10-26
NO20031914L (no) 2003-06-23
NO20031914D0 (no) 2003-04-29
PE20020518A1 (es) 2002-07-12
MY132777A (en) 2007-10-31
NZ526024A (en) 2005-10-28
WO2002036591A3 (de) 2002-07-25
SA01220503B1 (ar) 2007-03-10
HRP20030337A2 (en) 2005-04-30
BG107726A (bg) 2004-11-30
HK1060569A1 (en) 2004-08-13
CZ305033B6 (cs) 2015-04-08
IL155676A (en) 2012-05-31
UY26991A1 (es) 2002-06-20
UA76435C2 (en) 2006-08-15
ECSP034570A (es) 2003-06-25
IL155676A0 (en) 2003-11-23
WO2002036591A2 (de) 2002-05-10
TWI296934B (en) 2008-05-21
JP2004523482A (ja) 2004-08-05
JP4559703B2 (ja) 2010-10-13
KR20040010552A (ko) 2004-01-31
EE05343B1 (et) 2010-10-15
BG66425B1 (bg) 2014-04-30
ZA200303045B (en) 2004-04-22
EA200300483A1 (ru) 2003-12-25
HUP0301377A3 (en) 2005-12-28
CN1237970C (zh) 2006-01-25

Similar Documents

Publication Publication Date Title
US6890517B2 (en) Inhalable formulation of a solution containing a tiotropium salt
JP7015331B2 (ja) ロフルミラストｎ－酸化物の吸入によって自己免疫、呼吸器性および炎症性の障害を処置する方法
ES2276942T3 (es) Combinacion de un inhibidor de pde4 y tiotropio o un derivado del mismo para tratar vias respiratorias obstructivas y otras enfermedades inflamatorias.
AR038765A1 (es) Formulacion en solucion inhalable con una sal de tiotropio
EA014776B1 (ru) Фармацевтическая композиция для аэрозольного распыления с двумя действующими веществами и по меньшей мере одним поверхностно-активным веществом
RU2361593C3 (ru) Комбинация азеластина и стероидов
JP2008500990A5 (de)
JPH01153639A (ja) 鼻又は目に使用する薬剤及びその製造法
PE20060826A1 (es) Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
US20070117788A1 (en) Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases
PE20080607A1 (es) Formulacion en aerosol para la inhalacion de beta-agonistas
US20100144610A1 (en) Pharmaceutical formulations
KR20110123740A (ko) 5-(2-｛［6-(2,2-디플루오로-2-페닐에톡시)헥실］아미노｝-1-히드록시에틸)-8-히드록시퀴놀린-2(1ｈ)-온 및 이의 폐질환 치료에서의 용도
US20050107420A1 (en) Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
US20030064034A1 (en) Use of compounds in a dry powder inhaler
BR112015025781B1 (pt) Composição farmacêutica inalatória compreendendo 3 pós em que um primeiro pó contém budesonida, um segundo pó contém formoterol e um terceiro pó contém um agente de volume, e kit para a administração de um fármaco como um pó inalatório compreendendo tal composição
CN103736093A (zh) 一种包含咪唑斯汀及甾族化合物的药物制剂
WO2022007743A1 (zh) 粘膜给药剂型和其应用
BR102012008322A2 (pt) Formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa

Legal Events

Date Code Title Description
FC Refusal